Introduction to Valneva's Share Capital
Valneva is a leading biotechnology company dedicated to developing and commercializing innovative vaccines. This article presents a recent declaration detailing the company's share capital and the associated voting rights as of the specified date.
Key Details of the Declaration
Valneva has announced important information on its share capital, effective as of a recent date. The company holds a total of 162,494,003 ordinary shares, each with a nominal value of €0.15.
Voting Rights Overview
The total number of voting rights, including those that may be suspended, stands at 178,365,675. This figure plays a critical role in assessing the company's governance and shareholder engagement.
Recent Changes and Developments
Several significant changes have occurred in Valneva's share capital. The changes include a transfer into bearer form of 208 shares with double voting rights and the definitive allocation of 217,102 free ordinary shares. Additionally, double voting rights have been granted on 4,050 ordinary shares. Understanding these changes helps shareholders comprehend how these adjustments impact their rights and responsibilities.
Date of Recognition
These changes were recognized between October 8 and 10, aligning with specific adjustments occurring up until the end of October.
Importance of Voting Rights
A crucial aspect of any public company is the understanding of voting rights among shareholders. The voting rights define the influence shareholders can exert on company decisions. It’s worth noting that the theoretical voting rights are utilized as a baseline for calculating threshold crossings, an important concept in corporate governance.
Net Voting Rights Explained
Net voting rights, which can be exercised during a General Meeting, were reported to be 178,241,353. This number excludes any suspended voting rights, focusing on the active participation potential for shareholders during meetings.
Conclusion
These insights into Valneva's share capital and voting rights underscore the company's transparency in its corporate governance practices. As Valneva continues to advance its vaccine development initiatives, understanding these details is vital for investors and stakeholders alike.
Frequently Asked Questions
What is the significance of Valneva's share capital declaration?
The declaration provides transparency on the number of shares and voting rights, essential for investors assessing their influence within the company.
How many ordinary shares does Valneva currently have?
Valneva currently has 162,494,003 ordinary shares, each with a nominal value of €0.15.
What are double voting rights, and how do they affect shareholders?
Double voting rights provide shareholders with increased voting power, which can affect major decisions within the company.
When were the recent changes in voting rights recognized?
The recent changes in voting rights were recognized between October 8 and 10, including updates throughout October.
Why is it essential to understand net voting rights?
Net voting rights indicate the actual voting power available to shareholders, excluding any rights that may be suspended, thus allowing for informed voting decisions at General Meetings.
